IN8bio, Inc. (INAB) Stock

IN8bio, Inc. (INAB) is a Healthcare stock trading at $1.27 (as of 2026-08-21), with a market capitalization of $12.52M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

IN8bio, Inc. is a clinical-stage biotechnology company developing gamma-delta T cell therapies for cancer. Its pipeline includes INB-200, an autologous genetically modified gamma-delta T cell candidate in Phase I for glioblastoma and solid tumors, and INB-100, an allogeneic candidate in Phase I for acute leukemia patients undergoing hematopoietic stem cell transplantation.

Understand IN8bio, Inc.: how it makes money

IN8bio, Inc. develops gamma-delta T cell therapies for cancer, and aims to make money by advancing its therapy candidates through clinical development toward future commercialization.

The companys profit potential is structurally dependent on whether its gamma-delta T cell therapy candidates (such as INB-200 and INB-100) can successfully progress from early clinical trials to later-stage development and commercialization.

Business quality (Weak): Limited data is available here for reportable segments and operating KPIs, so the investor takeaways focus on program stage (Phase I) and the clinical-development execution risk.

Bull case

  • Multiple gamma-delta T cell programs in clinical development: INB-200 is in Phase I for glioblastoma and solid tumors, and INB-100 is in Phase I for acute leukemia patients undergoing hematopoietic stem cell transplantation.
  • Broad development pipeline beyond the lead candidates: The company also develops INB-400 and INB-300, which can expand future options if earlier programs perform well.

Bear case

  • Very early stage clinical exposure: Both lead candidates are described as being in Phase I, which is typically associated with higher uncertainty around safety and efficacy.
  • No reported operating metrics or segment structure in the provided data: With no operating KPIs or reportable segments provided here, it is harder to track progress with the specific metrics investors usually use for biotech performance.
Valuation — source: SEC EDGAR (first-party)
Price$1.27
Market Cap$12.52M
Price / Book0.68
Price / Sales20.23
FCF Yield-84.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$421000.00
Net Margin-4617.6%
Revenue Growth (YoY)83.0%
EPS Growth (YoY)678.9%
Financial Health — source: SEC EDGAR
Altman Z-Score-5.60 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderAlyeska Investment Group, L.P. ($1.40M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOTai-Wei
Employees18
CountryUS
IPO Date2021-07-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Jasper Therapeutics, Inc. (JSPR)
  • Dyadic International, Inc. (DYAI)
  • CEL-SCI Corporation (CVM)
  • Intensity Therapeutics, Inc. (INTS)
  • Passage Bio, Inc. (PASG)
  • Senti Biosciences, Inc. (SNTI)
  • Creative Medical Technology Holdings, Inc. (CELZ)
  • VivoSim Labs, Inc. (VIVS)
INAB earnings history · INAB institutional & insider holders · INAB KPIs & operating metrics · INAB financials · INAB investor presentations & press releases · INAB SEC filings · INAB peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.